Universal Loss Dynamics in a Unitary Bose Gas

The low temperature unitary Bose gas is a fundamental paradigm in few-body and many-body physics, attracting wide theoretical and experimental interest. Here we first present a theoretical model that describes the dynamic competition between two-body evaporation and three-body re-combination in a harmonically trapped unitary atomic gas above the condensation temperature. We identify a universal magic trap depth where, within some parameter range, evaporative cooling is balanced by recombination heating and the gas temperature stays constant. Our model is developed for the usual three-dimensional evaporation regime as well as the 2D evaporation case. Experiments performed with unitary 133 Cs and 7 Li atoms fully support our predictions and enable quantitative measurements of the 3-body recombination rate in the low temperature domain. In particular, we measure for the first time the Efimov inelasticity parameter $\eta$ * = 0.098(7) for the 47.8-G d-wave Feshbach resonance in 133 Cs. Combined 133 Cs and 7 Li experimental data allow investigations of loss dynamics over two orders of magnitude in temperature and four orders of magnitude in three-body loss. We confirm the 1/T 2 temperature universality law up to the constant $\eta$ *

Global transcriptional control by glucose and carbon regulator CcpA in Clostridium difficile.

International audienceThe catabolite control protein CcpA is a pleiotropic regulator that mediates the global transcriptional response to rapidly catabolizable carbohydrates, like glucose in Gram-positive bacteria. By whole transcriptome analyses, we characterized glucose-dependent and CcpA-dependent gene regulation in Clostridium difficile. About 18% of all C. difficile genes are regulated by glucose, for which 50% depend on CcpA for regulation. The CcpA regulon comprises genes involved in sugar uptake, fermentation and amino acids metabolism, confirming the role of CcpA as a link between carbon and nitrogen pathways. Using combination of chromatin immunoprecipitation and genome sequence analysis, we detected 55 CcpA binding sites corresponding to ∼140 genes directly controlled by CcpA. We defined the C. difficile CcpA consensus binding site (cre(CD) motif), that is, 'RRGAAAANGTTTTCWW'. Binding of purified CcpA protein to 19 target cre(CD) sites was demonstrated by electrophoretic mobility shift assay. CcpA also directly represses key factors in early steps of sporulation (Spo0A and SigF). Furthermore, the C. difficile toxin genes (tcdA and tcdB) and their regulators (tcdR and tcdC) are direct CcpA targets. Finally, CcpA controls a complex and extended regulatory network through the modulation of a large set of regulators

A prospective, observational study of fidaxomicin use for Clostridioides difficile infection in France.

To describe the characteristics, management and outcomes of hospitalised patients with Clostridioides difficile infection (CDI) treated with and without fidaxomicin. This prospective, multicentre, observational study (DAFNE) enrolled hospitalised patients with CDI, including 294 patients treated with fidaxomicin (outcomes recorded over a 3-month period) and 150 patients treated with other CDI therapies during three 1-month periods. The primary endpoint was baseline and CDI characteristics of fidaxomicin-treated patients. At baseline, the fidaxomicin-treated population included immunocompromised patients (39.1%) and patients with severe (59.2%) and recurrent (36.4%) CDI. Fidaxomicin was associated with a high rate of clinical cure (92.2%) and low CDI recurrence (16.3% within 3 months). Clinical cure rates were ≥90% in patients aged ≥65 years, those receiving concomitant antibiotics and those with prior or severe CDI. There were 121/296 (40.9%) patients with adverse events (AEs), 5.4% with fidaxomicin-related AEs and 1.0% with serious fidaxomicin-related AEs. No fidaxomicin-related deaths were reported. Fidaxomicin is an effective and well-tolerated CDI treatment in a real-world setting in France, which included patients at high risk of adverse outcomes.Trial registration: Description of the use of fidaxomicin in hospitalised patients with documented Clostridium difficile infection and the management of these patients (DAFNE), NCT02214771, www.ClinicalTrials.gov

WSES guidelines for management of Clostridium difficile infection in surgical patients

In the last two decades there have been dramatic changes in the epidemiology of Clostridium difficile infection (CDI), with increases in incidence and severity of disease in many countries worldwide. The incidence of CDI has also increased in surgical patients. Optimization of management of C difficile, has therefore become increasingly urgent. An international multidisciplinary panel of experts prepared evidenced-based World Society of Emergency Surgery (WSES) guidelines for management of CDI in surgical patients.Peer reviewe

Infections à

Clostridium difficile est un bacille à Gram positif anaérobie, sporulé, responsable de 15 à 25 % des diarrhées post-antibiotiques et de plus de 95 % des cas de colites pseudo-membraneuses. Les principaux facteurs de risque d’infections liées à C. difficile sont l’âge supérieur à 65 ans, l’administration d’antibiotiques (notamment de céphalosporines de troisième génération, de l’association amoxicilline et acide clavulanique, de clindamycine et de fluoroquinolones dont le rôle semble de plus en plus prépondérant) et les antécédents d’hospitalisation. Ces dernières années ont été marquées par l’apparition de formes plus sévères d’infections liées à la dissémination rapide, en Amérique du Nord et en Europe, d’un clone épidémique de PCR-ribotype 027 particulièrement virulent